Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03772028 · ClinicalTrials.gov registry record · Phase 3
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
A Phase 3 study of Ovarian Cancer, sponsored by The Netherlands Cancer Institute.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 538
- Enrollment target
- 20
- Study locations
NCT03772028 is a Phase 3 study of Ovarian Cancer that is actively recruiting participants, run by The Netherlands Cancer Institute. The registered enrollment target is 538 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT03772028, a Phase 3 study of Ovarian Cancer, is actively recruiting participants, sponsored by The Netherlands Cancer Institute.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 538 participants
- Enrollment target
- 20
- Study locations
Study Summary
stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
Conditions Studied
Interventions
- DRUG cisplatin
Study Locations (20)
Other
- Rigshospitalet Copenhagen - Copenhagen
- CHU de Besancon - Besançon
- Institut Bergonié - Bordeaux
- o Institut Bergonié, Bordeaux - Bordeaux
- CHU Lille - Lille
- Centre Leon Berard, Lyon - Lyon
- CHU Lyon - Lyon
- Institut du Cancer Montpellier - Montpellier
- Institut de Cancerologie de l'Ouest, ICO Nantes) - Nantes
- Institut Curie Paris - Paris
- CHRU Strasbourg - Strasbourg
- Oncopole, Institute Universitaire du Cancer de Toulouse (IUCT Toulouse) - Toulouse
- Mater Misericordiae University Hospital, Dublin - Dublin
- Policlinico Sant'Orsola, Bologna - Bologna
- Fondazione Policlinico A Gemelli IRCCS - Roma
- Amsterdam UMC - Amsterdam
- Catharina Hospital - Eindhoven
California
- City of Hope - Duarte
New York
- MSKCC New York - New York
North Holland
- Antoni van leeuwenhoek - Amsterdam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 538 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03772028
The ClinicalTrials.gov registry entry for NCT03772028 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 538 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (26% lower). The listed sponsor is The Netherlands Cancer Institute, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which cisplatin is the first listed.
NCT03772028 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT03772028 about?
NCT03772028 is a clinical study titled "Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)". stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
What is the current status of trial NCT03772028?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 538 participants. The study started on 2020-01-01. Estimated completion is 2026-04-01.
What conditions does trial NCT03772028 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT03772028?
The interventions under investigation include: cisplatin (DRUG).
Who is sponsoring clinical trial NCT03772028?
This trial is sponsored by The Netherlands Cancer Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03772028 being conducted?
This trial has 20 study locations across California, New York, North Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.